PBAC
Changes to PBS restrictions for antidepressants backed
PBAC makes recommendation to amend 30-day solid oral dosage-form listings for several low-cost antidepressants from restricted to unrestricted benefits Amendments to the Pharmaceutical Benefits Scheme (PBS) listing restrictions for 14 antidepressants …
PBAC backs ADHD meds listing change
Changes to PBS restrictions for atomoxetine and guanfacine for the treatment of ADHD are being supported by the PBAC The Pharmaceutical Benefits Advisory Committee (PBAC) is backing a move to broaden access …
PBAC go-ahead for adrenaline nasal spray
PBS listing recommendation for neffy, with PBAC citing previous shortages of adrenaline auto-injector pens The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended the listing of neffy nasal spray, for the …
The price ain’t right: Lilly
Positive funding recommendation for Mounjaro came with “unviable and unsustainable conditions”, sponsor says Eli Lilly is calling for “wholesale changes” to be made to the PBS (Pharmaceutical Benefits Scheme) after withdrawing its application …
Cost ‘major barrier’ to access, patients lowering doses
Resounding support for subsidising GLP-1s for obesity treatment, PBS public consultation submissions show, with quality of medicines issues present Submissions from 491 consumers, 25 health professionals and 23 organisations to …
‘A necessary step’
First PBAC recommendation for Covid vaccine addition to NIP The Pharmaceutical Benefits Advisory Committee (PBAC) has recommended that the Covid-19 vaccine, Comirnaty, be listed on the National Immunisation Program (NIP) …
Wegovy backed for PBS listing
PBAC recommends “risk sharing arrangement” to fund PBS listing of Wegovy for established cardiovascular disease with obesity Pricing could be key for Novo Nordisk to get Wegovy (semaglutide) listed on …
‘Rapid’ uptake of CF triple therapy
PBS listing of the combination medicine has led to improved quality of life for patients with cystic fibrosis (CF), says drug utilisation committee Nearly 90% of Australians prescriptions of cystic …
Prescriber Bag reviewed
Furosemide, Covid-19 antiviral tablets cited in PBAC recommendations on items to be added to or removed from the bag All currently listed Prescriber Bag benefits remain suitable, except Covid-19 antiviral …
Frustration over lack of progress following HTA review
Efforts to speed up the PBS listing process for new medicines are underwhelming, Senator says More than a year after the Accelerating access to the best medicines for Australians now …
‘Disconnect’ between PBS listings, guidelines
PBAC and experts debate PBS restrictions following its rejection for listing of new therapy The PBAC and other experts have investigated “several disconnections” in currently available medicines for pulmonary arterial …
Renewed PBS bid for Wegovy
PBAC to consider semaglutide listing for new indication of established CVD with obesity The PBAC will soon consider whether Novo Nordisk’s Wegovy (semaglutide 2.4mg) should be subsidised for Australians with …